预测1年存活率对于心力衰竭（HF）患者的风险分层至关重要;然而，关于HF患者合并癌症的1年预后知之甚少。因此，我们的目标是研究乳腺癌、胃肠癌或肺癌患者新发HF后1年的预后，根据癌症状态进行分层分析。纳入2000-2018年间丹麦所有新发HF患者。将癌症状态分为癌症史（HF诊断后五年内没有与癌症相关的接触）、无活动性癌症（接受治疗意图为治愈性的手术）和活动性癌症。使用G-computation报告标准化1年总因果死亡率。使用Kaplan-Meier估计器估计年龄分层的1年总因果死亡率。总计纳入193,359名HF患者，其中7.3%患有乳腺癌、胃肠癌或肺癌。癌症患者年龄较大，伴发疾病更多。乳腺癌史、胃肠癌史和肺癌史的标准化1年总因果死亡率（95%置信区间）分别为24.6%（23.0%-26.2%）、27.1%（25.5%-28.6%）和29.9%（25.9%-34.0%），与无活动性癌症患者相当。活动性乳腺癌、胃肠癌和肺癌的标准化1年总因果死亡率分别为36.2%（33.8%-38.6%）、49.0%（47.2%-50.9%）和61.6%（59.7%-63.5%）。年龄增长与1年总因果死亡率呈递增关系，但对于活动性肺癌来说并非如此。不论癌症类型为癌症史或无活动性癌症患者的标准化1年总因果死亡率相当，但对于活动性癌症患者则变化较大。年龄对于活动性肺癌的预后影响有限。因此，对于新发HF患者的优化管理，需要对癌症进行细致分层。此文章受版权保护，所有权利保留。

Expected 1-year survival is essential to risk stratification of patients with heart failure (HF); however, little is known about the 1-year prognosis of patients with HF and cancer. Thus, the objective was to investigate the 1-year prognosis following new-onset HF stratified by cancer status in patients with breast-, gastrointestinal-, or lung cancer.All Danish patients with new-onset HF from 2000-2018 were included. Cancer status was categorized as history of cancer (no cancer-related contact within five years of HF diagnosis), non-active cancer (curative intended procedure administered) and active cancer. Standardized 1-year all-cause mortality was reported using G-computation. Age-stratified 1-year all-cause mortality was estimated using the Kaplan-Meier estimator. In total, 193 359 patients with HF were included, 7.3% had either a breast-, gastrointestinal or lung cancer diagnosis. Patients with cancer were older and more comorbid than patients without cancer. Standardized 1-year all-cause mortalities (95% confidence intervals) were 24.6% (23.0%-26.2%), 27.1% (25.5%-28.6%), and 29.9% (25.9%-34.0%) for history of breast-, gastrointestinal-, and lung cancer, which was comparable to patients with non-active cancers. For active breast-, gastrointestinal-, and lung cancer, standardized 1-year all-cause mortalities were 36.2% (33.8%-38.6%), 49.0% (47.2%-50.9%), and 61.6% (59.7%-63.5%), respectively. One-year all-cause mortality increased incrementally with age, except for active lung cancer.Standardized 1-year all-cause mortality were comparable for patients with history of cancer and non-active cancer regardless cancer type, but varied comprehensively for active cancers. Prognostic impact of age was limited for active lung cancer. Thus, granular stratification of cancer is necessary for optimized management of new-onset HF. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.